Seattle Genetics Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital
October 26, 2018 7:35 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $92.00 (from $98.00) while maintaining a Outperform rating.
The analyst notes the surprise Adcetris miss brings questions to 1L HL aspect of bull thesis.
... MoreSeattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook
October 25, 2018 5:40 PM EDTSeattle Genetics (NASDAQ: SGEN) is down 16% after-hours after the company reported Q3 EPS of ($0.34), $0.07 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $169.4 million versus the consensus estimate of $166.92 million.
The company sees Q4 ADCETRIS net product sales of $128-$133 million and FY 2018 ADCETRIS net product sales of $473-$478 million.
ADCETRIS... More
